etrials Worldwide to Report First Quarter 2009 Financial Results

etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of adaptive eClinical software and services designed to optimize clinical trial management by turning data into intelligence and shortening the pathway to an actionable study endpoint, today announced it will release financial results for the three months ended March 31, 2009 on Tuesday, May 12, 2009, at 4:30 PM EST, after the markets close. During the call, M. Denis Connaghan, etrials� president and chief executive officer, and Joseph (Jay) Trepanier III, chief financial officer, will discuss the Company�s quarterly performance and financial results.

To participate in the live earnings call by telephone, please dial 800-480-2207, or, for international callers, please dial 706-643-7866 and reference ID number 97058686. Those interested in listening to the conference call live via the Internet may do so by visiting the Company�s Web site at www.etrials.com. Please go to the Web site 15 minutes prior to the scheduled start to register, and install any necessary audio software. A Web cast audio replay and a telephone audio replay will also be available for two weeks following the call by dialing 800-642-1687 from the US or 706-645-9291 for international callers, and entering conference ID number 97058686 when prompted.

About etrials(R)

Headquartered near North Carolina�s Research Triangle Park, etrials Worldwide, Inc. (Nasdaq: ETWC), is a leading provider of eClinical software and services to pharmaceutical, biotechnology, medical device companies, as well as contract research organizations, offering adaptive, Web-based tools that work together to coordinate data capture, logistics, patient interaction and trial management � turning data into intelligence and shortening the pathway to an actionable study endpoint. etrials is one of the few top-tier solution providers that offers electronic data capture (EDC), interactive voice and Web response (IVR/IWR) and electronic patient diaries (eDiary), as part of a flexible and integrated software-as-a-service (SaaS) platform or as individual solutions to capture high quality data from multiple pivot points to enable real-time access for informed decision-making. As an experienced leader, etrials has facilitated over 900 trials involving more than 400,000 patients in 70 countries and has participated in 42 studies that resulted in 14 approved new drug applications and/or regulatory approvals. To learn more visit us at www.etrials.com.

Forward-Looking Statements

This announcement may contain forward-looking statements. These statements involve risks and uncertainties. Actual results could differ materially from those discussed. More information about potential factors which could cause actual results to differ from the forward-looking statements included in this announcement is included in our filings with the Securities and Exchange Commission, including the "Risk Factors" Section of the Form 10-K filed on March 10, 2009. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements.

etrials� is the registered trademark in the United States of etrials Worldwide, Inc. Other marks belong to their respective owners and are used with permission.

Etrials Worldwide (MM) (NASDAQ:ETWC)
Historical Stock Chart
From Oct 2024 to Nov 2024